• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.
 
  • Détails
Titre

Outcomes following implantation of the Biolimus A9-eluting BioMatrix coronary stent: Primary analysis of the e-BioMatrix registry.

Type
recension de livre
Institution
Externe
Périodique
Catheterization & Cardiovascular Interventions  
Auteur(s)
Urban, P.
Auteure/Auteur
Valdés, M.
Auteure/Auteur
Menown, I.
Auteure/Auteur
Eberli, F.
Auteure/Auteur
Alhaddad, I.
Auteure/Auteur
Hildick-Smith, D.
Auteure/Auteur
Iosseliani, D.
Auteure/Auteur
Roffi, M.
Auteure/Auteur
Oldroyd, K.
Auteure/Auteur
Kalloudi, E.
Auteure/Auteur
Eerdmans, P.
Auteure/Auteur
Berland, J.
Auteure/Auteur
Kleber, F.X.
Auteure/Auteur
Contributrices/contributeurs
Metzler, B.
Weidinger, F.
Christ, G.
Kala, P.
Cervinka, P.
Carstensen, S.
Kische, S.
Mulvihill, N.
Mahon, N.
Alhaddad, I.A.
Erglis, A.
Unikas, R.
Chaara, A.
Boukili, A.
Lesiak, M.
Kalawski, B.
Fernandes, R.
Kozlov, K.L.
Iosseliani, D.G.
Picó-Aracil, F.
García, B.
Ramón Rumoroso, J.
Lopez Palop, R.
Berenguer, A.
Trillo, R.
Valdés Chavarri, M.
Rodriguez Collado, J.
Urban, P.
Eberli, F.
Templin, C.
Weilenmann, D.
Cook, S.
Goy, J.J.
Roffi, M.
Pedrazzini, G.
Windecker, S.
Hill, J.
Menown, I.
Oldroyd, K.
Uren, N.
Cotton, J.
Aziz, S.
Blackman, D.
O'Rourke, B.
Lowe, R.
Talwar, S.
Sarkar, D.
Grech, E.
Hildick Smith, D.
El-Omar, M.
Clarke, S.
Spence, M.
Walsh, S.
Goode, G.
Kukreja, N.
Witherow, F.
Bagnall, A.
Signy, M.
Chieffo, A.
Kastrati, A.
Peruga, J.Z.
Poerner, T.C.
Wöhrle, J.
Radke, P.
Mauri, F.
Albarran, A.
Moreno, R.
Roguelov, C.
Girod, G.
Birkemeyer, R.
Rosenberg, M.
Lyon, X.
Jensen, L.
Urban, P.
Roffi, M.
Hildick-Smith, D.
Oldroyd, K.
Kleber, F.X.
Valdés, M.
Berland, J.
Iosseliani, D.
Alhaddad, I.
Eberli, F.
Menown, I.
Piault, R.
Eerdmans, P.
Meis, S.
Groupes de travail
e-Biomatrix investigators
Liens vers les personnes
Girod, Grégoire  
ISSN
1522-726X
Statut éditorial
Publié
Date de publication
2015-12-01
Volume
86
Numéro
7
Première page
1151
Dernière page/numéro d’article
1160
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
To assess the safety and efficacy of Biolimus A9-eluting stents (BES, BioMatrix™ and BioMatrix Flex™) in routine clinical practice.
The LEADERS randomized trial has documented equivalent efficacy and superior safety of the BES when compared to a first generation Sirolimus-eluting Cypher(TM) stent.
5,472 patients from 57 centers, treated with BES, were enrolled in an international multicenter registry and followed clinically up to 2 years.
Mean patient age was 63.2 ± 11 years, 24% of patients had diabetes, and 49.8% presented with an acute coronary syndrome. 99.3% of patients were discharged on dual antiplatelet therapy (DAPT), 83.3% remained on DAPT at 1 year and 30.6% at 2 years. The incidence of the composite primary end point [major adverse cardiac events (MACE) at 12 months] was 4.5% [cardiac death 0.9%, myocardial infarction 1.7%, clinically indicated target vessel revascularization (ci-TVR) 2.8%]. MACE incidence was 6.8% at 24 months (cardiac death 1.5%, myocardial infarction 2.4%, ci-TVR 4.3%). At 12 months, 32 patients (0.6%) had suffered at least one definite or probable stent thrombosis (ST), and 91 patients (1.7%) a major bleed (MB). Nine patients with ST (27.3%) and 7 patients with a MB (7.7%) died during the first year after the index procedure. Between 12 and 24 months after implantation, there were 18 (0.4%) additional MB and 8 (0.2%) additional ST.
This large international cohort documents a low 12 and 24 months MACE incidence and a very low ST incidence in an unselected patient population undergoing BES implantation. The results are in keeping with those of the randomized controlled LEADERS trial. Even though ST with this stent was a rare event, it was still associated with significant mortality. MB remains a problem, and warrants improved tailoring of DAPT in recipients of drug eluting stents.
Sujets

Aged

Cardiovascular Agents...

Comorbidity

Coronary Artery Disea...

Coronary Artery Disea...

Coronary Artery Disea...

Coronary Thrombosis/e...

Coronary Thrombosis/m...

Drug Therapy, Combina...

Drug-Eluting Stents

Female

Humans

Incidence

Kaplan-Meier Estimate...

Male

Middle Aged

Myocardial Infarction...

Myocardial Infarction...

Percutaneous Coronary...

Percutaneous Coronary...

Percutaneous Coronary...

Platelet Aggregation ...

Proportional Hazards ...

Registries

Risk Factors

Sirolimus/administrat...

Sirolimus/analogs & d...

Time Factors

Treatment Outcome

bleeding

drug eluting stent

dual antiplatelet the...

stent thrombosis

PID Serval
serval:BIB_CCB0CC3653EC
DOI
10.1002/ccd.25892
PMID
25683225
WOS
000365323400002
Permalien
https://iris.unil.ch/handle/iris/199449
Open Access
Oui
Date de création
2017-08-22T14:26:34.282Z
Date de création dans IRIS
2025-05-21T02:32:33Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

ccd.25892.pdf

Version du manuscrit

preprint

Licence

https://iris.unil.ch/disclaimer

Taille

522.83 KB

Format

Adobe PDF

PID Serval

serval:BIB_CCB0CC3653EC.P001

Somme de contrôle

(MD5):b487fe584290db4bdd41a8181881fcde

  • Copyright © 2024 UNIL
  • Informations légales